Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question Response

被引：5

作者：

Fojo, Tito ^{[2
]}

Grady, Christine ^{[1
]}

机构：

[1] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA

[2] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2010年 / 102卷 / 15期

关键词：

PHASE-III TRIAL; BEVACIZUMAB; CHEMOTHERAPY; SORAFENIB; CARCINOMA; PACLITAXEL; EFFICACY; SAFETY;

D O I：

10.1093/jnci/djq247

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1207 / U121

页数：4

共 19 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[2] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[3] Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Staehler, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Anderson, Sibyl ;

Hofilena, Gloria ;

Shan, Minghua ;

Pena, Carol ;

Lathia, Chetan ;

Bukowski, Ronald M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318

[4] Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].

Feldman, Darren R. ;

Baum, Michael S. ;

Ginsberg, Michelle S. ;

Hassoun, Hani ;

Flombaum, Carlos D. ;

Velasco, Susanne ;

Fischer, Patricia ;

Ronnen, Ellen ;

Ishill, Nicole ;

Patil, Sujata ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1432-1439

[5] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].

Friedman, Henry S. ;

Prados, Michael D. ;

Wen, Patrick Y. ;

Mikkelsen, Tom ;

Schiff, David ;

Abrey, Lauren E. ;

Yung, W. K. Alfred ;

Paleologos, Nina ;

Nicholas, Martin K. ;

Jensen, Randy ;

Vredenburgh, James ;

Huang, Jane ;

Zheng, Maoxia ;

Cloughesy, Timothy .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740

[6] A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer [J].

Hecht, J. Randolph ;

Mitchell, Edith ;

Chidiac, Tarek ;

Scroggin, Carroll ;

Hagenstad, Christopher ;

Spigel, David ;

Marshall, John ;

Cohn, Allen ;

McCollum, David ;

Stella, Philip ;

Deeter, Robert ;

Shahin, Seta ;

Amado, Rafael G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :672-680

[7] Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes [J].

Hortobagyi, Gabriel N. ;

Gomez, Henry L. ;

Li, Rubi K. ;

Chung, Hyun-Cheol ;

Fein, Luis E. ;

Chan, Valorie F. ;

Jassem, Jacek ;

Lerzo, Guillermo L. ;

Pivot, Xavier B. ;

Hurtado de Mendoza, Fernando ;

Xu, Binghe ;

Vahdat, Linda T. ;

Peck, Ronald A. ;

Mukhopadhyay, Pralay ;

Roche, Henri H. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (02) :409-418

[8] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].

Kreisl, Teri N. ;

Kim, Lyndon ;

Moore, Kraig ;

Duic, Paul ;

Royce, Cheryl ;

Stroud, Irene ;

Garren, Nancy ;

Mackey, Megan ;

Butman, John A. ;

Camphausen, Kevin ;

Park, John ;

Albert, Paul S. ;

Fine, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745

[9] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

[10] Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 [J].

Lynch, Thomas J. ;

Patel, Taral ;

Dreisbach, Luke ;

McCleod, Michael ;

Heim, William J. ;

Hermann, Robert C. ;

Paschold, Eugene ;

Iannotti, Nicholas O. ;

Dakhil, Shaker ;

Gorton, Steven ;

Pautret, Virginie ;

Weber, Martin R. ;

Woytowitz, Donald .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :911-917

← 1 2 →